Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A

Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A

SSZSE:301126
8.38
CNY
-0.25
(-2.90%)
-1.09EPS
2.16BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A carries a market capitalization of 2.16B, placing it among publicly traded companies globally. Its enterprise value stands at 5.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.16B
Enterprise Value5.39B

Share Statistics

As of September 30, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A has 205.40M shares outstanding.

Shares Outstanding205.40M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 0.42, and the price-to-book ratio stands at 1.44.

PS Ratio0.42
PB Ratio1.44
P/TBV Ratio7.92

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 1.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.39B versus a market cap of 2.16B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.07

Financial Position

As of September 30, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A maintains a current ratio of 1.01, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 208.81, indicating elevated leverage, while an interest coverage ratio of -3.68 demonstrates limited ability to service its debt obligations.

Current Ratio1.01
Quick Ratio0.08
Debt / Equity208.81
Debt / EBITDA-16.13
Interest Coverage-3.68

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A posted a negative return on equity (ROE) of -14.61, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.73, reflecting losses generated across the asset base. The company generates approximately 946,156.66 in revenue per employee across its workforce of 5,339.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.66 indicates how many times Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-14.61
Return on Assets (ROA)-3.73
Revenue Per Employee946,156.66
Employee Count5,339.00
Inventory Turnover4.66

Taxes

CNY

Over the twelve months ended September 30, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A recorded 7.29M in income tax expense. The company reported a pretax loss of -214.79M and -237.77M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax7.29M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A's stock has declined approximately 34.68% over the past 52 weeks. The 50-day moving average sits at 9.74, while the 200-day moving average is 10.56.

52-Week Price Change-34.68%
50-Day Moving Average9.74
200-Day Moving Average10.56

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A generated 5.05B in revenue and converted that into -237.77M in net income, yielding earnings per share of -1.09. EBITDA reached -210.89M, while operating income came in at 112.81M.

Revenue5.05B
Gross Profit975.52M
Operating Income112.81M
Pretax Income-214.79M
Net Income-237.77M
EBITDA-210.89M
EBIT-210.89M
Earnings Per Share (EPS)-1.09

Balance Sheet

CNY

As of September 30, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A holds 303.16M in cash and equivalents against 3.40B in total debt, resulting in a net debt position of 2.71B. Total book value stands at 1.50B, with working capital of 55.19M providing operational flexibility.

Cash & Cash Equivalents303.16M
Total Debt3.40B
Net Debt2.71B
Equity (Book Value)1.50B
Book Value Per Share7.29
Working Capital55.19M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-71.60M

Margins

Over the twelve months ended September 30, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A posted a gross margin of 19.31, reflecting its pricing power and cost economics. The operating margin of 2.23 and net profit margin of -4.71 provide insight into operational efficiency.

Gross Margin19.31
Operating Margin2.23
Pretax Margin-4.25
Profit Margin-4.71
EBITDA Margin-4.17

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A paid dividends of 0.26 per share. The dividend payout ratio of -25.63 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.79, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A shareholders.

Dividend Per Share0.26
Payout Ratio-25.63
Shareholder Yield3.79

Scores

As of September 30, 2026, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A has an Altman Z-Score of 1.48, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.48